Avanir Pharmaceuticals Message Board
-
130M Gross Annual R, 97.5M Net Annual R will
get us to break even, so nearing the halfway point?
-
Today, the Company said OPEX is going down NOT UP this quarter - in fact all the way down to $19.9 to $21.9 MM which is BY FAR the lowest number this Fiscal Year. In fact, OPEX was lower in FY Q3 than FY Q2 as well.
Those are the facts. OPEX has been AND is continuing to go down not up. If you have any facts that indicates otherwise, please provide the link.
When AVNR does issue guidance for next Fiscal Year ending 9/2013, we will then have some facts to base any forecasts on. Otherwise, it is just pure speculation. nothing more.
Who knows, an EU partner could assume the ongoing costs of the MS pain and ALZ agitation studies. -
They previously guided for FY13 OPEX at $95-105M. Given that are upping this year's guidance I'd expect the upper end of that range.
If they have OPEX of $100M next year then to break even they'd need Net revenues of $106M at today's gross margin rate of 94.4%
If they need $106M Net (may be too low) and the discount rate is 22.5% then they need gross of $136.7M
THUS, if current gross run rate is $52M we are 38% of the way to BE.- 2 Replies to onlyfactsplease
-
Today, AVNR guided FY Q4 OPEX down from $19.9MM to $21.9 MM which is $94 to $96 MM for the Fiscal Year ending 9/30/12. They already have $74.2 MM of OPEX in the first 3 quarters of this fiscal year. As a result, there are only $19.9 to $21.9 MM left for Q4.
Thus, this quarter's expenses are going down again and will be significantly less than the quarter just ended 6/30.
To my knowledge, AVNR has never guided for the FY ending 9/30/2013. If otherwise, please provide a link. -
Thanks OF, I'm getting it, slowly but surely, LOL.
-